Ikarian Capital, LLC Intellia Therapeutics, Inc. Transaction History

Ikarian Capital, LLC

  • $573 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$38.49 - $76.21 $1.82 Million - $3.61 Million
-47,408 Closed
0 $0
Q1 2022

May 13, 2022
BUY
$58.27 - $118.99 $2.76 Million - $5.64 Million
47,408 New
47,408 $3.45 Million
Q2 2020

Aug 14, 2020
SELL
$11.14 - $22.87 $2.06 Million - $4.23 Million
-184,989 Closed
0 $0
Q1 2020

May 15, 2020
BUY
$9.44 - $15.58 $1.75 Million - $2.88 Million
184,989 New
184,989 $2.26 Million

Others Institutions Holding NTLA

# of Institutions
314
Shares Held
91.5M
Call Options Held
442K
Put Options Held
880K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $916M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email